Fever (87.9%) early on (43%)	Myalgia or Arthralgia (14.8%)	Nasal Congestion (4.8%)
Dry Cough (67.7%)	Sore Throat (13.9%)	Diarrhea (3.7%)
Fatigue (38.1%)	Headache (13.6%)	Hemoptysis (0.9%)
Sputum Production (33.4%)	Chills (11.4%)	Conjunctival Congestion (0.8%)
Shortness of breath (18.6%)	Nausea or Vomiting (5.0%)	
LICUIST DISV.	MODERATE RISH	LOW BISK
HIGHEST RISK:	MODERATE RISK:	LOW RISK:
FEVER or COUGH or DYSPNEA or other	FEVER or COUGH or DYSPNEA or other	Symptoms not strongly compatible
compatible symptoms	compatible symptoms	AND
PLUS:	AND:	No direct contact exposure to persons, no
ANY PERSON INCLUDING HEALTH CARE	History TO A MODERATELY AFFECTED AREA in	travel
WORKERS WITH A CONTACT of a lab con-	14 days, or an evolving area	
firmed OR suspected case in 14 days	OR CONCERN about exposure to a suspected	
OR	person	
History of TRAVEL TO A GEOGRAPHICALLY	Notify MA or PCP	
AFFECTED AREA in 14 days (Italy, Iran, China,	If PCP, after reviewing the risk for exposure,	
South Korea)	determines COVID-19 testing is appropriate:	
esting:	Testing:	Testing:
Patient with face mask		Patient with face mask—WAIT in sick

- Patient with face mask COVID visit-follow FLOWCHART for MA in
- PPE assessment at car of Flu, oxygen saturation

- Patient with face mask

saturation

- COVID visit-follow FLOWCHART for MA in PPE assessment at car of Flu, oxygen

PPE: surgical mask, eye protection, gloves

- Patient with face mask—WAIT in sick waiting room
- MD evaluation for alternate diagnosis Follow infection control as needed for the clinical scenario

MA wears infection control: AIRBORNE/